Trinity Biotech PLC (FRA:TRB)
€ 2.12 0 (0%) Market Cap: 20.08 Mil Enterprise Value: 79.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 54/100

Trinity Biotech PLC at Piper Sandler Healthcare Conference Transcript

Dec 01, 2022 / 03:30PM GMT
Release Date Price: €6.25 (-0.79%)
Aris Kekedjian
Trinity Biotech PLC - Chairman & CEO

Thank you. Good morning. I'm Aris Kekedjian, CEO and Chairman of Trinity Biotech. I've been in that role for exactly two months now, and I wanted to give you an introduction to the company and our strategy.

Trinity is a global IVD company. For those of you don't know, we provide centralized diagnostic products, lateral flow, point-of-care products, and lab-based testing services. It's pretty diversified company based in now Bray, Ireland.

One of the reasons that I joined the company was effectively for the for the investment thesis, the opportunity to grow and scale a platform and the breadth and diversity of Trinity. And I have listed here kind of the six key reasons why you want to invest in Trinity. If you're going to do it, it's the same reason why I joined the company.

It's a diversified global platform in large, high-growth diabetes and autoimmune spaces that have a lot of potential. And at the same time, we're well placed in the fast-evolving point-of-care and home testing spaces.

The company ex-COVID is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot